subjects there was an increase in bronchial hyperresponsiveness only during the first two weeks of the study, but by the end of four weeks this increase had disappeared. In the study of Vathenen et al (ref 7) with eight asthmatic subjects it was observed that a (rebound) increase in hyperresponsiveness occurred, not whilst using the 13 agonist but afterwards. In our own study (ref 14) an increase in hyperresponsiveness was observed when using a.0 agonist in a selected group of 15 patients. These 15 patients were selected on the condition that they had not used any 1 agonists or 1 blockers for one year before the start of the study. They were part of a much larger group of 144 6 Wilson C, Lincoln C. 13-adrenoceptor subtypes in human, rat, guinea-pig and rabbit atria. J
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